 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- AG01 / A&G Pharma
On-going phase 1A clinical trial of A01, a chimerized monoclonal antibody to Progranulin/Glycoprotein 88 (GP88) in patients with advanced malignancy. (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_1889;
P1a
A first-in-human, first-in-class phase 1 safety and efficacy clinical study of AG01 in patients with solid tumors and advanced disease with special focus on patients with breast, lung and ovarian cancers has been initiated and is on-going at the University of Maryland Greenebaum Cancer Center...The presentation will provide an update on the number of patients enrolled in this on-going phase 1A trial. Supported by grants R44CA162629 and R44CA224718 from the National Cancer Institute to GS.
- AG01 / A&G Pharma
Development of fully human anti-progranulin monoclonal antibodies as inhibitors of triple negative breast cancer cell growth and tumor formation. (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_1443;
The use of the TC transgenic mice allows for the rapid development of fully human high affinity monoclonal antibodies bypassing the need for chimerization or humanization of mouse monoclonal antibodies. The development of fully human anti-progranulin antibodies provides novel targeted therapeutic option for TNBC.
- AG01 / A&G Pharma
On-going phase 1A clinical trial for AG01 an first-in-class anti-progranulin (GP88) monoclonal antibody in patients with advanced malignancies (Section 46; Poster Board #3) - Mar 14, 2023 - Abstract #AACR2023AACR_7129;
P1a
The IND application has been filed and cleared by the Food and Drug Administration. A first-in-human, first-in-class phase 1 safety and efficacy clinical study of AG01 in patients with solid tumors and advanced disease with special focus on patients with breast, lung and ovarian cancers has been initiated and is on-going at the University of Maryland Greenebaum Cancer Center.
- AG01 / A&G Pharma
Anti-progranulin (GP88) antibody AG01 inhibitory effect on the growth of triple negative breast cancer cells (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_1447;
PGRN/GP88 represents a therapeutic target for TNBC with two companion diagnostics (tissue test and ELISA to measure GP88 circulating levels). Blocking PGRN/GP88 with AG01 antibody treatment will provide novel targeted therapeutic option for TNBC which could address the issue of toxicity, and unresponsiveness associated with SOC.
- | AG01 / A&G Pharma
Journal: Anti-progranulin/GP88 antibody AG01 inhibits triple negative breast cancer cell proliferation and migration. (Pubmed Central) - Jun 24, 2021
PGRN/GP88 represents a therapeutic target with companion diagnostics. Blocking PGRN/GP88 with antibody treatment may provide novel-targeted solutions in TNBC treatment which could eventually address the issue of toxicity and unresponsiveness associated with SOC.
- | AG01 / A&G Pharma, Thelmox (mebendazole) / Remedica
Preclinical, Journal: Mebendazole induces apoptosis via C-MYC inactivation in malignant ascites cell line (AGP01). (Pubmed Central) - Jan 27, 2020
MBZ induced lower cell viability in AGP01 cells compared AGP01 shRNA MYC in the same concentration. Therefore, our results show the evidence of C-MYC gene as one of the pathways by which MBZ induces cell death in gastric cancer cells.
- | AG01 / A&G Pharma
Journal: A Novel Three-Dimensional Analysis of Tongue Movement During Water and Saliva Deglutition: A Preliminary Study on Swallowing Patterns. (Pubmed Central) - Jan 17, 2020
Fourteen participants (25.36 ± 4.85 years) were evaluated, and the movements of anterior, middle, and posterior portions of the tongue were recorded using AG501 3D-electromagnetic articulograph...The movement of the tongue portions was influenced by the volume and the element to be swallowed. The amplitude of the movement was directly proportional to the volume of water swallowed.
- | AG01 / A&G Pharma
Journal: New prognostic markers revealed by RNA-Seq transcriptome analysis after MYC silencing in a metastatic gastric cancer cell line. (Pubmed Central) - Oct 26, 2019
Metastatic GC cells (AGP01) characterized by MYC amplification, were transfected with siRNAs targeting MYC...Overall survival rate of patients with overexpressed CIAPIN1 or UXT was significantly lower (P < 0.0001). In conclusion, CIAPIN1 and UXT may serve as potential molecular markers for GC prognosis.
- | AG01 / A&G Pharma
Journal: Characterization of Telomerase (hTERT) in Solid and Hematopoietic Cancer Cell Lines Reveals Different Expression Patterns. (Pubmed Central) - Sep 27, 2019
In conclusion, CIAPIN1 and UXT may serve as potential molecular markers for GC prognosis. In leukemia cell lines, hTERT gene overexpression was shown to be a potential target for pharmacological assays for drugs aiming to inhibit telomerase activity and control cell proliferation in oncohematological diseases.
- | AG01 / A&G Pharma
Journal: Diversification of Bw4 Specificity and Recognition of a Nonclassical MHC Class I Molecule Implicated in Maternal-Fetal Tolerance by Killer Cell Ig-like Receptors of the Rhesus Macaque. (Pubmed Central) - Jul 19, 2019
These results reveal an expansion of the lineage II KIRs in macaques that recognize Bw4 ligands and identify a nonclassical molecule implicated in placental development and pregnancy as a ligand for Mamu-KIR3DL05. In addition to offering new insights into KIR-MHC class I coevolution, these findings provide an important foundation for investigating the role of NK cells in the rhesus macaque as an animal model for infectious diseases and reproductive biology.